Alpha 2.0
Login Register
» Articles » PMID: 3618128

Proliferative Potential of Meningiomas Determined with the Monoclonal Antibody Ki-67

Overview
Journal Acta Neuropathol
Specialty Neurology
Date 1987 Jan 1
PMID 3618128
Citations 31
Authors
W Roggendorf
T Schuster
J PEIFFER
Affiliations
Soon will be listed here.
Abstract

In 30 meningiomas we investigated the proliferation rate of various subtypes with the monoclonal antibody Ki-67. Frozen sections were incubated with Ki-67 antibody using a modified Alkaline Phosphatase anti-Alkaline Phosphatase (APAAP)-technique and evaluation of proliferation rate was done by cell counting. Meningiomas of the meningiotheliomatous, fibrous and angioblastic subtype without atypical histological findings contained 1% or less proliferating cells. In recurrent tumors, in transitional and in anaplastic meningiomas there is a marked increase of proliferating cells up to 20%. The distribution of marked cells varies in recurrent tumors and anaplastic meningiomas, and a focal proliferation of tumor cells was seen in meningiomas from transitional type. Immunohistological labelling of proliferating cells in meningiomas may allow a more precise prediction of the proliferation potential of each meningioma.

Citing Articles

Topographic Patterns of Intracranial Meningioma Recurrences-Systematic Review with Clinical Implication.

Corvino S, Altieri R, La Rocca G, Piazza A, Corazzelli G, Palmiero C Cancers (Basel). 2024; 16(12).

PMID: 38927972 PMC: 11201517. DOI: 10.3390/cancers16122267.

Contrast enhanced magnetic resonance imaging-based radiomics nomogram for preoperatively predicting expression status of Ki-67 in meningioma: a two-center study.

Ouyang Z, He S, Zeng Y, Zhu Y, Ling B, Sun X Quant Imaging Med Surg. 2023; 13(2):1100-1114.

PMID: 36819280 PMC: 9929424. DOI: 10.21037/qims-22-689.

Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index.

Teranishi Y, Okano A, Miyawaki S, Ohara K, Ishigami D, Hongo H Acta Neuropathol Commun. 2022; 10(1):76.

PMID: 35570314 PMC: 9107722. DOI: 10.1186/s40478-022-01377-w.

Meningioma Tumor Microenvironment.

Sahab-Negah S, Gorji A Adv Exp Med Biol. 2021; 1296:33-48.

PMID: 34185285 DOI: 10.1007/978-3-030-59038-3_3.

Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature.

Chen Y, Tiang X, Li Z, Luo B, Huang Q Diagn Pathol. 2010; 5:39.

PMID: 20565869 PMC: 2904739. DOI: 10.1186/1746-1596-5-39.

References
1.
Burger P, Shibata T, Kleihues P . The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol. 1986; 10(9):611-7. DOI: 10.1097/00000478-198609000-00003. View
2.
Gerdes J, Schwab U, Lemke H, STEIN H . Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31(1):13-20. DOI: 10.1002/ijc.2910310104. View
3.
Cordell J, Falini B, Erber W, Ghosh A, Abdulaziz Z, MacDonald S . Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984; 32(2):219-29. DOI: 10.1177/32.2.6198355. View
4.
Nagashima T, DeArmond S, Murovic J, Hoshino T . Immunocytochemical demonstration of S-phase cells by anti-bromodeoxyuridine monoclonal antibody in human brain tumor tissues. Acta Neuropathol. 1985; 67(1-2):155-9. DOI: 10.1007/BF00688136. View
5.
Petty A, Kun L, Meyer G . Radiation therapy for incompletely resected meningiomas. J Neurosurg. 1985; 62(4):502-7. DOI: 10.3171/jns.1985.62.4.0502. View